Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 26:14:25158414211070878.
doi: 10.1177/25158414211070878. eCollection 2022 Jan-Dec.

Ocular adverse effects of therapeutic biologics

Helio V Neves da Silva  1 , John Placide  2 , Anne Duong  2 , Yasmyne Ronquillo  3 , Shannon McCabe  3 , Majid Moshirfar  4
Affiliations
Review

Ocular adverse effects of therapeutic biologics

Helio V Neves da Silva et al. Ther Adv Ophthalmol. .

Abstract

Biological drugs, termed biologics, are medications that contain or are derived from a living organism (human, animal, or microorganism). With new biological agents being approved by the Food and Drug Administration (FDA) every year, clinicians need to know potential ocular adverse effects that are associated with these drugs. This review provides an overview of ocular adverse effects of biological medications used to treat both ophthalmic and non-ophthalmic diseases. We searched PubMed for relevant case reports, case series, reviews, and clinical trials reporting ocular adverse effects caused by biologics. This review was conducted in June 2021 and investigated the drugs listed in the most updated (April 2021) FDA Purple Book Database of Licensed Biological Products. This review focuses on monoclonal antibodies, interleukins, and receptor fusion proteins. We explore ocular side effects of 33 biological drugs, stating whether they are frequent, common, or rare.

Keywords: biological medications; biologics; ocular adverse effects; ocular side effects; ocular toxicity; ophthalmic side effects.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Cluster of differentiation and cell types targeted by different monoclonal antibodies.
Figure 2.
Figure 2.
Cellular responses to interactions between growth factors and receptors.
Figure 3.
Figure 3.
Immune checkpoint inhibitors influencing interactions between T-cells and target cells via different ligands.
See this image and copyright information in PMC

References

    1. Hager T, Seitz B. Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 2013; 7: 69–77. - PMC - PubMed
    1. Fortes BH, Tailor PD, Dalvin LA. Ocular toxicity of targeted anticancer agents. Drugs 2021; 81: 771–823. - PubMed
    1. Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye 2018; 32: 287–301. - PMC - PubMed
    1. Liu CY, Francis JH, Brodie SE, et al.. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 2014; 34: 1261–1280. - PubMed
    1. Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. FDA, https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-... (accessed 14 June 2021).

LinkOut - more resources